Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shing M Lee

Showing results (51-60 of 62) with videos related to

Pageof 7
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2021
A Phase I Study of the Combination of Pexidartinib and Sirolimus to Target Tumor-Associated Macrophages in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath TumorsGulam A Manji, Brian A Van Tine, Shing M Lee, et al.
Journal of Neurotrauma|October 7, 2009
The citicoline brain injury treatment (COBRIT) trial: design and methodsRoss Zafonte, William T Friedewald, Shing M Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2022
Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical TrialsJoseph M Unger, Riha Vaidya, Kathy S Albain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2010
Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphomaJia Ruan, Peter Martin, Richard R Furman, et al.
Journal of the National Cancer Institute|November 21, 2002
Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancerHsueh-Wei Chang, Shing M Lee, Steven N Goodman, et al.
The Journal of Urology|March 3, 2020
A Phase I Trial of Intravesical Cabazitaxel, Gemcitabine and Cisplatin for the Treatment of Nonmuscle Invasive bacillus Calmette-Guérin Unresponsive or Recurrent/Relapsing Urothelial Carcinoma of the BladderGuarionex J DeCastro, Wilson Sui, Jamie S Pak, et al.
Breast Cancer Research and Treatment|July 2, 2021
Diffuse optical tomography breast imaging measurements are modifiable with pre-surgical targeted and endocrine therapies among women with early stage breast cancerJulia E McGuinness, Mirella L Altoe, Alessandro Marone, et al.
The Oncologist|March 18, 2026
Phase 2 Study of Azacitidine plus Pembrolizumab as Second-Line Treatment in Patients with Locally Advanced or Metastatic Pancreatic Ductal AdenocarcinomaRachael A Safyan, Ruth A White, Tamas A Gonda, et al.
Journal of the American Medical Informatics Association : JAMIA|December 1, 2020
Towards clinical data-driven eligibility criteria optimization for interventional COVID-19 clinical trialsJae Hyun Kim, Casey N Ta, Cong Liu, et al.
Journal of Clinical and Translational Science|April 27, 2026
Return of results is important to heterogeneous research participants: A single-site surveySheila M O'Byrne, Ismael Castaneda, Rayheann-NaDeja Collins, et al.
Pageof 7

Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2021
A Phase I Study of the Combination of Pexidartinib and Sirolimus to Target Tumor-Associated Macrophages in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath TumorsGulam A Manji, Brian A Van Tine, Shing M Lee, et al.
Journal of Neurotrauma|October 7, 2009
The citicoline brain injury treatment (COBRIT) trial: design and methodsRoss Zafonte, William T Friedewald, Shing M Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2022
Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical TrialsJoseph M Unger, Riha Vaidya, Kathy S Albain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2010
Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphomaJia Ruan, Peter Martin, Richard R Furman, et al.
Journal of the National Cancer Institute|November 21, 2002
Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancerHsueh-Wei Chang, Shing M Lee, Steven N Goodman, et al.
The Journal of Urology|March 3, 2020
A Phase I Trial of Intravesical Cabazitaxel, Gemcitabine and Cisplatin for the Treatment of Nonmuscle Invasive bacillus Calmette-Guérin Unresponsive or Recurrent/Relapsing Urothelial Carcinoma of the BladderGuarionex J DeCastro, Wilson Sui, Jamie S Pak, et al.
Breast Cancer Research and Treatment|July 2, 2021
Diffuse optical tomography breast imaging measurements are modifiable with pre-surgical targeted and endocrine therapies among women with early stage breast cancerJulia E McGuinness, Mirella L Altoe, Alessandro Marone, et al.
The Oncologist|March 18, 2026
Phase 2 Study of Azacitidine plus Pembrolizumab as Second-Line Treatment in Patients with Locally Advanced or Metastatic Pancreatic Ductal AdenocarcinomaRachael A Safyan, Ruth A White, Tamas A Gonda, et al.
Journal of the American Medical Informatics Association : JAMIA|December 1, 2020
Towards clinical data-driven eligibility criteria optimization for interventional COVID-19 clinical trialsJae Hyun Kim, Casey N Ta, Cong Liu, et al.
Journal of Clinical and Translational Science|April 27, 2026
Return of results is important to heterogeneous research participants: A single-site surveySheila M O'Byrne, Ismael Castaneda, Rayheann-NaDeja Collins, et al.
Pageof 7